ijms-logo

Journal Browser

Journal Browser

Special Issue "Immunological Investigations in Hematology"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Immunology".

Deadline for manuscript submissions: 30 September 2020.

Special Issue Editor

Prof. Dr. Athanasia Mouzaki
Website
Guest Editor
Division of Hematology, Department of Internal Medicine, University of Patras Medical School, Patras, Greece
Interests: cellular and molecular immunology; immunohematology; T-cells; cytokines; transcription; HIV-1; autoimmunity

Special Issue Information

Dear Colleagues,

This thematic Special Issue will focus on the immune system as an active participant in hematology and hematologic diseases. Immune cells and soluble mediators are major components of blood and lymphoid tissues, are involved directly in immune-mediated hematologic diseases, and are used as diagnostic and therapeutic tools in all aspects of hematology.

We welcome research or review papers on immune system involvement in hematology, including, but not limited to, the following topics:

  1. The role of immune cells and cytokines in hematology and hematologic diseases;
  2. Immune biomarkers for hematologic diseases;
  3. Immunomodulators in hematology and hematologic diseases;
  4. Immunotherapeutic approaches to hematologic diseases (including CAR T-cells);
  5. Immunodiagnostic tools for hematologic diseases.

Prof. Dr. Athanasia Mouzaki
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Antibodies
  • Antigen-presenting cells
  • Autoantigens
  • Autoimmune hematologic diseases
  • B-cells
  • CAR T-cells
  • Cytokines
  • Diagnosis
  • Gene expression
  • Genetically engineered molecules
  • Immune cell malignancies
  • Immune hemolytic anemia
  • Immune therapy
  • Immune thrombocytopenic purpura (ITP)
  • Inherited blood disorders
  • Post-translational modifications
  • T-cells
  • Thalassemias
  • Therapy
  • Transplantation

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Delayed NK Cell Reconstitution and Reduced NK Activity Increased the Risks of CMV Disease in Allogeneic-Hematopoietic Stem Cell Transplantation
Int. J. Mol. Sci. 2020, 21(10), 3663; https://doi.org/10.3390/ijms21103663 - 22 May 2020
Abstract
Cytomegalovirus (CMV) infection has a significant impact in patients after allogeneic hematopoietic stem cell transplantation (HSCT). We investigated natural killer (NK) cell reconstitution and cytotoxic/cytokine production in controlling CMV infection, especially severe CMV disease in HSCT patients. Fifty-eight patients with acute myeloid leukemia [...] Read more.
Cytomegalovirus (CMV) infection has a significant impact in patients after allogeneic hematopoietic stem cell transplantation (HSCT). We investigated natural killer (NK) cell reconstitution and cytotoxic/cytokine production in controlling CMV infection, especially severe CMV disease in HSCT patients. Fifty-eight patients with acute myeloid leukemia (AML) who received allo-HSCT were included. We monitored NK reconstitution and NK function at baseline, 30, 60, 90, 120, 150, and 180 days after HSCT, and compared the results in recipients stratified on post-HSCT CMV reactivation (n = 23), non-reactivation (n = 24) versus CMV disease (n = 11) groups. The CMV disease group had a significantly delayed recovery of CD56dim NK cells and expansion of FcRγ-CD3ζ+NK cells started post-HSCT 150 days. Sequential results of NK cytotoxicity, NK cell-mediated antibody-dependent cellular cytotoxicity (NK-ADCC), and NK-Interferon-gamma (NK-IFNγ) production for 180 days demonstrated delayed recovery and decreased levels in the CMV disease group compared with the other groups. The results within 1 month after CMV viremia also showed a significant decrease in NK function in the CMV disease group compared to the CMV reactivation group. It suggests that NK cells’ maturation and cytotoxic/IFNγ production contributes to CMV protection, thereby revealing the NK phenotype and functional NK monitoring as a biomarker for CMV risk prediction, especially CMV disease. Full article
(This article belongs to the Special Issue Immunological Investigations in Hematology)
Show Figures

Figure 1

Back to TopTop